Antiangiogenic properties of prostate‐specific antigen (PSA)

References

• Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001; 22(2)184–204
   PubMed Web of Science ®Google Scholar
• Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387(6)637–41
   PubMed Web of Science ®Google Scholar
• Lövgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate‐specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997; 238(2)549–55
   PubMed Web of Science ®Google Scholar
• Paju A, Bjartell A, Zhang WM, Nordling S, Borgström A, Hansson J, Stenman UH. Expression and characterization of trypsinogen produced in the human male genital tract. Am J Pathol 2000; 157(6)2011–21
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007; 1776(1)22–31
   PubMed Web of Science ®Google Scholar
• Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate‐specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997; 272(34)21582–8
   PubMed Web of Science ®Google Scholar
• Emami N, Diamandis EP. Human kallikrein‐related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. J Biol Chem 2008; 283(6)3031–41
   PubMed Web of Science ®Google Scholar
• Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate‐specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci. USA 1986; 83(10)3166–70
   PubMed Web of Science ®Google Scholar
• Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. Substrate specificity of prostate‐specific antigen (PSA). Chem Biol 1998; 5(9)475–88
   PubMedGoogle Scholar
• Lilja H. A kallikrein‐like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76(5)1899–903
   PubMed Web of Science ®Google Scholar
• Robert M, Gibbs BF, Jacobson E, Gagnon C. Characterization of prostate‐specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 1997; 36(13)3811–9
   PubMed Web of Science ®Google Scholar
• Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4(11)876–90
   PubMed Web of Science ®Google Scholar
• Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41(3)265–312
   PubMed Web of Science ®Google Scholar
• Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?. Prostate 2007; 67(3)312–29
   PubMed Web of Science ®Google Scholar
• Koistinen H, Närvänen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P, Stenman UH. Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem 2008; 389(6)633–42
   PubMed Web of Science ®Google Scholar
• Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate‐specific antigen in endocrine‐treated prostate carcinomas. Clin Cancer Res 2000; 6(1)160–5
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988; 12(1)39–46
   PubMed Web of Science ®Google Scholar
• Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A. Increased expression of Tumor‐Associated Trypsin Inhibitor, TATI, in prostate cancer and in androgen‐independent 22Rv1 cells. Eur Urol 2007; 52(6)1670–9
   PubMed Web of Science ®Google Scholar
• Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate‐specific antigen. Semin Cancer Biol 1999; 9(2)83–93
   PubMed Web of Science ®Google Scholar
• Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon‐Gibod L, Ekman P. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol 2005, Suppl. 216: 64–81
   Google Scholar
• Lilja H, Ulmert D, Vickers AJ. Prostate‐specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8(4)268–78
   PubMed Web of Science ®Google Scholar
• Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clin Chim Acta 2007; 381(1)78–84
   PubMed Web of Science ®Google Scholar
• Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary‐like structures. J Cell Biol 1988; 107(4)1589–98
   PubMed Web of Science ®Google Scholar
• Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H. Structural characterization and anti‐angiogenic properties of prostate‐specific antigen isoforms in seminal fluid. Prostate 2008; 68(9)945–54
   PubMed Web of Science ®Google Scholar
• Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate‐specific antigen. J Natl Cancer Inst 1999; 91(19)1635–40
   PubMedGoogle Scholar
• Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland‐Linn J, Vu H, Plum SM, Nelson BJ. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003; 56(3)212–9
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate‐specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001; 48(1)1–6
   PubMed Web of Science ®Google Scholar
• Koistinen H, Wohlfahrt G, Mattsson JM, Wu P, Lahdenpera J, Stenman UH. Novel small molecule inhibitors for prostate‐specific antigen. Prostate 2008; 68(11)1143–51
   PubMed Web of Science ®Google Scholar
• Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH. Identification of novel prostate‐specific antigen‐binding peptides modulating its enzyme activity. Eur J Biochem 2000; 267(20)6212–20
   PubMedGoogle Scholar
• Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Generation of angiostatin‐like fragments from plasminogen by prostate‐specific antigen. Br J Cancer 1999; 81(8)1269–73
   PubMed Web of Science ®Google Scholar
• Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001; 33(4)357–69
   PubMed Web of Science ®Google Scholar
• Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65(10)3967–79
   PubMed Web of Science ®Google Scholar
• Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, Sugimura Y, Yoshikawa K, Hayward SW, Hirano K. Evidence that the prostate‐specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett 2004; 207(1)79–87
   PubMed Web of Science ®Google Scholar
• Pezzato E, Sartor L, Dell'Aica I, Dittadi R, Gion M, Belluco C, Lise M, Garbisa S. Prostate carcinoma and green tea: PSA‐triggered basement membrane degradation and MMP‐2 activation are inhibited by (‐)epigallocatechin‐3‐gallate. Int J Cancer 2004; 112(5)787–92
   PubMed Web of Science ®Google Scholar
• Webber MM, Waghray A, Bello D. Prostate‐specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1(10)1089–94
   PubMed Web of Science ®Google Scholar
• Mattsson JM, Laakkonen P, Kilpinen S, Stenman UH, Koistinen H. Gene expression changes associated with the antiangiogenic activity of kallikrein‐related peptidase 3 (KLK3) on human umbilical vein endothelial cells. Biol Chem 2008; 389(6)765–71
   PubMed Web of Science ®Google Scholar
• Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, Chadha KC. Prostate‐specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 2005; 7(3)241–52
   PubMed Web of Science ®Google Scholar
• Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor‐inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998; 95(11)6355–60
   PubMed Web of Science ®Google Scholar
• Leu SJ, Lam SC, Lau LF. Pro‐angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 2002; 277(48)46248–55
   PubMed Web of Science ®Google Scholar
• Glesne DA, Zhang W, Mandava S, Ursos L, Buell ME, Makowski L, Rodi DJ. Subtractive transcriptomics: establishing polarity drives in vitro human endothelial morphogenesis. Cancer Res 2006; 66(8)4030–40
   PubMed Web of Science ®Google Scholar
• Schoenfeld J, Lessan K, Johnson NA, Charnock‐Jones DS, Evans A, Vourvouhaki E, Scott L, Stephens R, Freeman TC, Saidi SA, Tom B, Weston GC, Rogers P, Smith SK, Print CG. Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF‐A and PlGF. Angiogenesis 2004; 7(2)143–56
   PubMedGoogle Scholar
• Cline EI, Bicciato S, DiBello C, Lingen MW. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res 2002; 62(24)7143–8
   PubMed Web of Science ®Google Scholar
• Wu P, Zhu L, Stenman UH, Leinonen J. Immunopeptidometric assay for enzymatically active prostate‐specific antigen. Clin Chem 2004; 50(1)125–9
   PubMed Web of Science ®Google Scholar
• Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate‐specific antigen (PSA) is an insulin‐like growth factor binding protein‐3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75(4)1046–53
   PubMed Web of Science ®Google Scholar
• Koistinen H, Paju A, Koistinen R, Finne P, Lövgren J, Wu P, Seppälä M, Stenman UH. Prostate‐specific antigen and other prostate‐derived proteases cleave IGFBP‐3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP‐3. Prostate 2002; 50(2)112–8
   PubMed Web of Science ®Google Scholar
• Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL. Growth regulation of prostatic stromal cells by prostate‐specific antigen. J Natl Cancer Inst 1999; 91(19)1663–9
   PubMedGoogle Scholar
• Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF. Preferential production of latent transforming growth factor beta‐2 by primary prostatic epithelial cells and its activation by prostate‐specific antigen. J Cell Physiol 2005; 202(2)361–70
   PubMed Web of Science ®Google Scholar
• Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate‐specific antigen suggests an activation of latent TGF‐beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192(2)940–7
   PubMed Web of Science ®Google Scholar
• Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis MI. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate‐specific antigen expression in prostate cancer. Clin Cancer Res 2001; 7(6)1533–8
   PubMed Web of Science ®Google Scholar